banner

CATALENT BIOLOGICS

  • email
  • twitter
  • linkedin
  • facebook
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
The new line is expected to be operational by April 2021 and will add capacity to support the growing pipeline of clinical programs and...

Put your AAV on the Fast-Track to the Clinic
Summary:​ In this executive summary, Catalent Cell & Gene Therapy experts George Buchman, Ph.D., Research Fellow, and Bhargavi Kondragunta,...

Bio Process International East
Each year, more than 3200+ bioprocessing professionals representing 40+ countries attend BioProcess International in Boston to learn about...

UpTempoSM Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic
Home » Expert Content » Drug Substance Manufacturing » UpTempoSM Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from...

Partnering to Achieve Successful Development and GMP Compliance for Cell Therapies
Date: March 27, 2024 Program Duration: half-day (AM agenda & networking lunch) Location: JLABS @ TMC – 2450 Holcombe Blvd Suite J, Houston, TX...